Prognostic Value of the LATITUDE and CHAARTED Risk Criteria for Predicting the Survival of Men with Bone Metastatic Hormone-Naïve Prostate Cancer Treated with Combined Androgen Blockade Therapy: Real-World Data from a Japanese Multi-Institutional Study.
Takashi KawaharaShuko YoneyamaYoshio OhnoJunpei IizukaYasunobu HashimotoHideyasu TsumuraKen-Ichi TabataYoshihiro NakagamiKazunari TanabeMasatsugu IwamuraHiroji UemuraYasuhide MiyoshiPublished in: BioMed research international (2020)
The patients with CHAARTED high-volume disease or LATITUDE high-risk disease showed a shorter CRPC-free survival and a shorter OS than those in the CHAARTED low-volume disease group or in the LATITUDE low-risk group among Asian Japanese bone metastatic HNPC patients.
Keyphrases
- free survival
- prostate cancer
- end stage renal disease
- small cell lung cancer
- squamous cell carcinoma
- newly diagnosed
- bone mineral density
- chronic kidney disease
- peritoneal dialysis
- machine learning
- prognostic factors
- stem cells
- radical prostatectomy
- electronic health record
- patient reported outcomes
- artificial intelligence
- deep learning
- cell therapy